drugset / Trial / NCT01006785

Efficacy and Safety of DLBS1425 in Subjects With Advanced/Metastatic Breast Cancer

NCT01006785

Phase 2 Terminated 15 enrolled Dexa Medica Group
RandomizedParallel-groupOpen-labelTreatment

Summary

The purposes of this study are : * to investigate the safety and clinical efficacy of sole therapy with DLBS1425 in suppressing disease-(tumour) progression in subjects with advanced/metastatic breast cancer; and * to determine the minimal effective and safe dose of DLBS1425 in the therapy of advanced/metastatic breast cancer

Timeline

Start
2009-08
Primary completion
2012-03
Completion
2012-03

Drugs

EvaluationDrugModalityDoseRoute
Subject DLBS1425 Unknown 150 mg
Subject DLBS1425 Unknown 300 mg

Indications